Oral Delivery of Erythropoietin: An Innovative Drug Delivery Strategy for the Management of Anemia

Abstract

Erythropoietin (EPO) is a glycoprotein hormone widely used for the treatment of anemia associated with chronic kidney disease, cancer chemotherapy, and other hematological disorders. Despite its therapeutic importance, EPO is primarily administered through parenteral routes because of its large molecular size, poor gastrointestinal permeability, and susceptibility to enzymatic degradation. and weak permeability. Chronic injectable analysis likewise results in decreased patient agreement, dose spot responses, and increased healthcare burden. Recent breakthroughs in the incidence of drug drugs, accompanied by specific devoted effort to something spoken drug drugs, have reignited interest in the likelihood of oral erythropoietin presidency. The purpose and aim of the current study is to evaluate the chance of oral EPO presidency by orderly inspecting current EPO expression strategies, essay evidence, and pharmacokinetic results. A biography review was conducted by searching the principal biomedical information sources to draw news regarding the differing studies administered to consider the practicability and efficacy of spoken erythropoietin delivery systems, including nanoparticulate transmittal, mucoadhesive transmittal orders, colon-focused delivery, and EPO transport by way of FcRn. The results assembled from the preclinical studies, transported in different animal models, illustrated that the differing spoken EPO formulations were favorable and active in inducing determinable hematologic attributes, that is to say, hemoglobin and reticulocyte levels, despite the weak bioavailability. Comparison between the spoken and injectable EPO formulations also illustrated important hematologic properties in the specific oral EPO transmittal wholes (p <0.05). Despite the continuous concerns and complications, in the way that the susceptibility to concerns with atom and molecule degradation, weak assimilation, and measurement irregularities, innovative sciences have shown promise in a portion of food to overcome the hurdles. From the results, it seems expected skilled evidence suggests that the spoken administration of erythropoietin, though in the investigational step, is actually an extreme-impact innovation accompanying huge potential for radical changes in the administration and treatment of blood deficiency.